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Abstract 
This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, 
pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase 
replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase 
alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 
5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no 
deaths/life-threatening serious adverse events (SAEs). One Naïve patient withdrew for study drug-related SAEs (respiratory distress/chest discomfort). 
Infusion-associated reactions (IARs) affected 8 patients. Most treatment-emergent AEs/IARs were non-serious with mild-to-moderate intensity. At 
screening, 5 Switch patients tested positive for anti-avalglucosidase alfa antibodies; on-treatment, 2 Switch and 9 Naïve patients seroconverted. 
Post-infusion, avalglucosidase alfa plasma concentrations declined monoexponentially (t 1/2z ∼1.0 h). AUC was 5–6 ×higher in the 20 vs 5 mg/kg 
group. Pharmacokinetics were similar between Switch and Naïve groups and over time. Baseline quadriceps muscle glycogen was low ( ∼6%) 
in most patients, generally remaining unchanged thereafter. Exploratory efficacy parameters (pulmonary function/functional capacity) generally 
remained stable or improved. Avalglucosidase alfa’s well-tolerated safety profile and exploratory efficacy results support further avalglucosidase alfa 
development. 
© 2018 The Authors. Published by Elsevier B.V. 
Keywords: Alglucosidase alfa; Enzyme replacement therapy; Glycogen storage disease type II; Lysosomal acid α-glucosidase (GAA) deficiency; 
Avalglucosidase alfa (neoGAA); Late-onset Pompe disease (LOPD). 
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d1. Introduction 
Pompe disease, also known as glycogen storage disease
type II or acid maltase deficiency, is a progressive, rare
autosomal recessive disorder caused by mutations in the
gene that encodes acid α-glucosidase (GAA). Deficiency of
lysosomal GAA, an enzyme required for lysosomal glycogen
degradation, results in an accumulation of lysosomal and
eventually cytoplasmic glycogen [ 1 –3 ]. Accumulation of
glycogen in the lysosome results in lysosomal swelling and
rupture [4] . Pompe disease exists as a spectrum of phenotypes,
and is often classified by age and symptoms at onset.
Classical infantile Pompe disease (IOPD) presents shortly
after birth and is characterized by prominent cardiomyopathy,
progressive generalized hypotonia, and rapid progression;
patients generally die within the first year when untreated.
When Pompe disease has a more gradual onset (late-onset
Pompe disease; LOPD), it presents as a proximal myopathy
with respiratory muscle involvement including the diaphragm,
but without cardiomyopathy. In these children and adults,
the disease course is more variable [5] . Onset of clinical
symptoms typically may occur from any time after the
first year of life to as late as the eighth decade [6,7] ; a
small subset of patients present without cardiomyopathy at
< 1 year of age [5,6] . The vast majority of patients present
during adulthood. Pompe disease incidence varies depending
on patients’ ethnicity, geographical region, and between the
different phenotypes [1] . 
Muscle pathology in LOPD is characterized by progressive
muscle damage starting with intralysosomal glycogen to
accumulation of storage material [8] , autophagic build-up
[9] , loss of contractile structure [10] , muscle atrophy and
replacement by fat [ 11 –13 ], and concomitant progressive loss
of function [14] . This process may already start in early life
[15] and clinically diagnosed symptomatic patients’ health
and functional status may already be severely impaired at
presentation [15–17] . For symptomatic patients with LOPD,
the risk of wheelchair use increases by 13% and the risk of
ventilator dependency increases by 8% for each additional
post-diagnosis year without treatment [18] . Patients requiring
both a wheelchair and respiratory support have higher
mortality than those requiring neither (5-year survival: 74%
vs 95%, respectively; p < 0.002) [19] . 
Response to GAA replacement is determined by the
severity of damage at treatment initiation and extent of
lysosomal glycogen accumulation [15,20,21] , and by the
magnitude of muscle GAA uptake achieved on therapy
[22,23] . Alglucosidase alfa is approved worldwide [24,25] for
Pompe disease treatment. Initial clinical trials in IOPD
patients demonstrated that alglucosidase alfa treatment
prolonged both overall and invasive ventilation-free survival,
as well as generally improved cardiomyopathy, motor
skills, and independent functional capacity [26,27] . The
Late-Onset Treatment Study (LOTS) [28,29] , conducted in
children (aged ≥8 years) and adults with Pompe disease,
demonstrated that alglucosidase alfa stabilized respiratory
function and improved walking distance, and supported thepproval of alglucosidase alfa therapy for the whole spectrum
f Pompe disease. 
Alglucosidase alfa clears glycogen storage in cardiac
uscle more effectively than in skeletal muscle [20,27] ,
hich may, in part, reflect tissue differences in cation-
ndependent mannose 6-phosphate (CIM6P)/insulin growth
actor II (IGFII) receptor expression and enzyme uptake
26 –32] . Also, most LOPD patients, who typically have
ore residual GAA activity than patients with the infantile
orm, are generally spared cardiac involvement, indicating
hat cardiac muscle is likely to require less GAA activity
o prevent and remediate glycogen storage [2] . The cell-
urface CIM6P/IGFII receptor mediates cellular uptake
f exogenous GAA and targets it to the lysosomal
ompartment [33] . Thus, M6P levels and exposure enable
nzyme uptake and internalization, and increasing M6P on
he recombinant enzyme may increase achieved skeletal
uscle uptake [34] . Avalglucosidase alfa (neoGAA) is
 second-generation, glycoengineered recombinant GAA
eplacement therapy with increased bis-M6P levels on the
olecule in order to increase receptor-mediated uptake
 Fig. 1 ). 
Preclinical studies in a Pompe disease mouse model have
hown that compared with alglucosidase alfa, avalglucosidase
lfa has a 1000-fold higher binding affinity to M6P receptors
22,23] and greater glycogen clearance from muscle on
 mg alglucosidase alfa/mg avalglucosidase alfa basis,
.e., equivalent clearance to rhGAA at one-fifth the dose
22] . In GAA knockout mice, 4 mg/kg is the minimum
harmacologically active dose for cardiac and 12 mg/kg for
keletal muscle [35] . The first dose of avalglucosidase alfa
dministered to patients in our study was 5 mg/kg actual
ody weight, which was cumulatively based upon nonclinical
afety information, the maximum recommended starting
ose per the Food and Drug Administration guidance [36] ,
nternational Conference on Harmonization M3 guidance
37] , and the observed potency and pharmacologically active
ose of avalglucosidase alfa in all target tissues from
ultiple nonclinical studies in mice. Avalglucosidase alfa
oses were planned to be administered in an ascending
anner, and for each dose escalation the increment was 2-
old, and was supported by the monitoring of potential safety
ignals. This escalation strategy took into consideration the
harmacologically active dose of 12 mg/kg in skeletal muscle
rom preclinical studies [35] . 
The objectives of this open-label, ascending-dose study
NEO1; ClinicalTrials.gov identifier: NCT01898364) were
o evaluate the safety and tolerability of avalglucosidase
lfa, characterize its pharmacodynamic and pharmacokinetic
rofiles, and assess exploratory efficacy endpoints following
epeated dose administrations in adults with Pompe disease,
ho were either alglucosidase alfa-naïve (Naïve Group)
r had received alglucosidase alfa for ≥9 months (Switch
roup). We emphasize that this study was, by design, a
hase 1 study focusing on safety and enrolling a small
atient cohort; for this reason the efficacy assessments were
esignated by protocol as exploratory. 
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Fig. 1. Structures of (a) Alglucosidase alfa and (b) Investigational avalglucosidase alfa second-generation acid α-glucosidase replacement therapy. Increased 
bis-mannose 6-phosphate (M6P) levels on avalglucosidase alfa favor uptake by cation-independent M6P receptors. Fig. 1 b Reprinted (adapted) with permission 
from Zhou Q, et al. Bioconjugate Chem 2011;22:741–751. Copyright 2011 American Chemical Society. 
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i  . Patients and methods 
.1. Participants and study design 
This was a multicenter, multinational, open-label, 
scending dose study, with every-other-week intravenous 
IV) infusions of avalglucosidase alfa; the study design is
resented in Fig. 2 . 
Eligible patients were male or female, aged ≥18 years,
ith confirmed GAA enzyme deficiency from any tissue
ource and/or two confirmed pathogenic GAA gene variants,
nd without known cardiac hypertrophy. Samples for GAA
enotyping were taken at baseline, if historical samples
ere not available. Patients had to be able to walk 50 m
ithout stopping or using an assistive device and had to have
n upright forced vital capacity (FVC) of ≥50% predicted
ccording to Hankinson et al. [38] . Fertile women had to
est negative for pregnancy at baseline and, if sexually active,
se two acceptably effective contraception methods during
reatment. 
Patients were excluded if they were wheelchair-dependent, 
equired invasive ventilation, were participating in another
linical study using investigational treatments, or were,
n the opinion of the investigator, unable to adhere to
tudy requirements. Patients were also excluded if theyad clinically significant organic disease (apart from Pompe
isease symptoms), e.g., cardiovascular, hepatic, pulmonary, 
eurologic, or renal disease, or had other medical conditions,
erious intercurrent illness, or extenuating circumstance that,
n the opinion of the investigator, precluded participation in
he study or potentially decreased survival. Patients with MRI
ontraindications were also excluded. Conditions suggesting 
igh risk for allergy to avalglucosidase alfa, e.g., previous
oderate-to-severe anaphylactic reaction to alglucosidase 
lfa, immunoglobulin (Ig) E antibodies, and/or a history of
ustained high IgG antibody titers to alglucosidase alfa, were
xclusionary. 
Patients were screened within 90 days before study
nclusion and treatment initiation. For the Naïve Group,
keletal muscle MRI and biopsy and all baseline efficacy
ssessments were performed ≤21 days before avalglucosidase 
lfa initiation, and for the Switch Group, these were
erformed after the last alglucosidase alfa administration and
21 days before avalglucosidase alfa initiation. 
Eligible patients, either naïve to alglucosidase alfa therapy
Naïve Group) or previously treated with alglucosidase alfa
or ≥9 months (Switch Group), received every-other-week 
valglucosidase alfa IV infusions at 5, 10, or 20 mg/kg actual
ody weight, totaling 13 infusions over 24 weeks. Each
nfusion was administered stepwise, beginning at a slow
170 L.D.M. Pena, R.J. Barohn and B.J. Byrne et al. / Neuromuscular Disorders 29 (2019) 167–186 
Fig. 2. Study design. 
∗For the Naïve Group, skeletal muscle MRI and biopsy and all efficacy assessments were performed within 21 days before avalglucosidase alfa initiation; for 
the Switch Group, these were performed after the last alglucosidase alfa administration and ≤21 days before avalglucosidase alfa treatment. 
Exploratory efficacy assessments included: pulmonary function testing; 6-min walk test; Gait, Stair, Gowers’ maneuver, Chair test; Gross Motor Function 
Measure-88; Quick Motor Function Test; hand-held dynamometry test; and Pediatric Quality of life Inventory Multidimensional Fatigue Scale – Adult Report. 
W, Week; D, avalglucosidase alfa infusion; PTE, post-treatment evaluation; EOS, end of study visit; SR, safety review by Data Monitoring Committee. 
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t  initial rate and gradually increasing if there were no signs
of infusion-associated reactions (IARs), up to a maximum
of approximately 7 mL/kg/h; total infusion time depended on
dose. For management of mild IARs, infusion rate reductions
or temporary interruptions were allowed. For moderate-to-
severe or recurrent IARs, the investigator could consider using
pre-treatment medications (i.e., antihistamines, antipyretics,
and/or glucocorticoids), in addition to infusion rate reductions,
interruptions, or discontinuation, if necessary. 
Study duration for each patient was approximately
41 weeks from screening to study end. This included:
screening within 90 days before inclusion and treatment
initiation, a baseline evaluation, a 24-week treatment period
(Weeks 1–25), a post-treatment evaluation 2 weeks after the
last infusion (Week 27), and an end-of-study visit 4 weeks
after the final infusion (Week 29). 
The study protocol was approved by Independent Ethics
Committees/Institutional Review Boards at participating
centers (Supplementary Table S1). All patients provided
written informed consent. 
2.2. Safety 
Patients were continuously monitored throughout the
study for safety, including IARs, via patient-reported and/or
investigator-observed adverse events (AEs). Standard clinical
laboratory evaluations (biochemistry, hematology, urinalysis,
and vital signs) were assessed at screening/baseline and
at each biweekly clinic visit from Week 1 through
Week 25. Patients had a physical examination, 12-
lead electrocardiogram (ECG), and were weighed at
screening/baseline; physical examinations were also made ateeks 13 and 25, and ECG and body weight measurements
t Weeks 1, 13, and 25. Blood samples to test for
nti-avalglucosidase alfa antibodies, and for neutralizing
ntibodies in anti-avalglucosidase alfa antibodies-positive
atients, were collected at baseline (within 24 h before the
rst infusion) and at Weeks 1, 5, 9, 13, 17, 21, 25, and
7. In addition, for Switch Group patients, samples at
eeks 1 and 25 were analyzed for anti-alglucosidase alfa
ntibodies. IgE, complement, serum tryptase, and circulating
mmune complexes were tested only in patients with potential
ypersensitivity IARs. 
.3. Pharmacokinetics 
Blood samples for pharmacokinetic analysis were collected
t Weeks 1 (Day 1), 13, and 25, prior to avalglucosidase
lfa infusion, immediately before the infusion rate changed
rom 1 to 3 mg/kg/h, from 3 to 5 mg/kg/h, and from 5
o 7 mg/kg/h, immediately before the end of infusion (0 h),
nd at 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 h
fter the end of infusion. Avalglucosidase alfa activity was
etermined using a qualified, sensitive fluorometric assay,
ith 4-methylumbelliferyl- α- D -glucoside pyranoside as the
ubstrate; the lower limit of quantification was 13 ng/mL. 
The following pharmacokinetic parameters were calculated
or plasma concentrations of avalglucosidase alfa after
ingle and multiple doses using non-compartmental methods:
aximum plasma concentration observed (C max ); time to
each C max (t max ); area under the plasma concentration–time
urve (AUC) calculated using the trapezoidal method from
ime zero to the real-time t last (AUC last ); AUC extrapolated
o infinity (AUC ∞ ); terminal half-life (t 1/2z ; i.e., the terminal
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salf-life associated with the terminal slope [ λz ]); apparent
otal body clearance from plasma (CL); and volume of
istribution at steady-state (V ss ). 
.4. Pharmacodynamics 
The following pharmacodynamic parameters were 
ssessed after single and multiple dose administration of
valglucosidase alfa: skeletal muscle glycogen content by
RI; qualitative (T 1 -weighted Mercuri scoring; 1: normal,
: < 30% fat, 3: ≥30% to < 60% fat, and 4: ≥60% fat)
nd quantitative (3-point Dixon, T 2 ); fasted urinary glucose
etrasaccharide (Hex 4 ); and exploratory fasted plasma and
rine biomarkers. 
MRI and skeletal muscle biopsies were performed
t baseline (within 21 days before treatment start) and
ost-treatment (Week 27). Normal-appearing muscle tissue
determined by MRI guidance) was sampled to prevent
iopsy of fatty or fibrotic tissue. Glycogen content was
easured in skeletal muscle biopsies by computer-assisted
istomorphometric analysis (MetaMorph ®) of high-resolution 
ight microscopy sections as previously described [20,39] .
riefly, to quantify accurately the distribution of glycogen
cross the entire specimen, up to 10 epoxy resin blocks were
rocessed per sample-time point for each patient. One slide
rom each block was analyzed; values obtained were averaged
o obtain a mean ± standard deviation (SD) for each patient-
ime point. Data were expressed as the % tissue area occupied
y glycogen. 
Fasted urine Hex 4 and exploratory urine biomarker samples
ere collected at baseline, and every other week during
reatment, and the exploratory plasma samples were collected
t baseline, and Weeks 1, 3, 5, 9, 13, 17, 21, and 25;
ll samples were taken within 24 h before avalglucosidase
lfa infusion. The exploratory urine and plasma biomarker
nalyses are pending and will be reported separately in the
uture. 
.5. Exploratory efficacy 
Avalglucosidase alfa efficacy on functional capacity and
trength was evaluated using several functional outcome
easures. Exploratory assessments were made at baseline and
t Weeks 13 and 25 within 24 h before avalglucosidase alfa
nfusion; changes from baseline to Weeks 13 and 25 were
alculated. 
Pulmonary function testing followed American Thoracic 
ociety guidelines [40] and included the assessment of FVC,
orced expiratory volume in 1 s (FEV 1 ), maximal inspiratory
ressure (MIP), maximal expiratory pressure (MEP), and peak
xpiratory flow (PEF) in the upright and supine positions
only upright data are reported). The % of predicted normal
alues for MIP and MEP were calculated according to
vans and Whitelaw [41] and for the FVC, FEV 1 , and PEF
ccording to Hankinson et al. [38] . 
The 6-min walk test (6MWT) was conducted according
o American Thoracic Society guidelines [42] . Changes ineters walked from baseline and changes in % predicted from
aseline were calculated at each assessment point. Predicted
alues were calculated according to Enright and Sherrill [43] .
The Gait, Stair, Gowers’ Maneuver, Chair (GSGC) test
44] consists of four functional tests (gait, climbing stairs,
owers’ maneuver, and arising from a chair). Each test
s scored from 1 (normal function) to 7 (poor function)
nd the total score calculated by summing the four test
cores. Missing tasks were imputed as if subjects could
ot perform them. Gross Motor Function Measure-88
GMFM-88) assessment was developed specifically to detect
uantitative changes in gross motor function [45] . Of the
ve dimensions to the GMFM-88, two were evaluated in this
tudy: Dimensions D (standing) and E (walking, running, and
umping; GMFM-88-DE). The Quick Motor Function Test
QMFT) [46] , is an observer-administered test comprising 16
tems specifically difficult for Pompe disease patients. Items
re scored individually on a 5-point ordinal scale (0–4), with
 total for all items of 0–64 points; lower scores indicate
orse motor function. For the hand-held dynamometry (HHD)
est, the examiner held the dynamometer stationary while
he patient exerted a maximal force against it, making
 gradual increase in force and then completing a 4–5 s
sometric hold. Limb tests (shoulder, elbow, hip, knee, and
nkle) and grip strength were completed bilaterally because
ominant and non-dominant limbs may differ. Each muscle
roup was measured twice and the highest score analyzed.
ndividual test scores were summed for the upper and lower
ody. 
The 18-item Pediatric Quality of Life Inventory
ultidimensional Fatigue Scale – Adult Report, Standard 
ersion (PedsQL TM ) [47] encompasses three subscales:
eneral Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue.
ix general fatigue items measure lack of strength and
ndurance to complete activities of daily living, six sleep/rest
atigue items measure sleep problems and number of
aps/day, and six cognitive fatigue items measure the impact
f fatigue on attention and memory. Items are evaluated on a
-point Likert scale, reverse-scored, and linearly transformed
o a 1–100 scale. A total score was calculated as the mean
erived from the sum of the transformed items divided by
he number of items answered on the scales. Higher scores
enote better health-related quality of life. 
.6. Statistical methods 
In total, 21 patients were planned empirically to complete
he study; no formal sample size calculations were performed.
he full analysis set (all patients who received ≥1 complete
nfusion of avalglucosidase alfa), the safety analysis set (all
atients who received any amount of avalglucosidase alfa)
nd the pharmacokinetic analysis set (patients without any
ajor deviations related to study drug administration who
ad available pharmacokinetic data) comprised the same
atients. Demographic and baseline data for medical/surgical
istory and Pompe disease history were summarized using
ummary statistics for continuous variables and frequency 
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Enrolled: 24 patients
Switch Group
(prior alglucosidase alfa 
therapy for ≥9 months):
14 patients
10 mg/kg 
avalglucosidase
alfa:
4 patients
5 mg/kg 
avalglucosidase
alfa:
4 patients
20 mg/kg 
avalglucosidase
alfa:
6 patients
Completed:
4 patients
Completed:
3 patients
Completed:
5 patients
1 patient 
withdrew 
consent
1 patient 
withdrew 
consent
Naïve Group
(naïve to alglucosidase alfa 
therapy):
10 patients
10 mg/kg 
avalglucosidase
alfa:
3 patients
5 mg/kg 
avalglucosidase 
alfa:
4 patients
20 mg/kg 
avalglucosidase
alfa:
3 patients
Completed:
3 patients
Completed:
3 patients
Completed:
3 patients
1 patient 
discontinued 
due to SAE
SAE, serious adverse event
Fig. 3. Flow diagram for disposition of patients during the study. 
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d  distribution for categorical variables. Safety evaluation was
based on a review of descriptive statistics and individual
data for AEs, immunogenicity, clinical laboratory, vital
sign, and ECG parameters. Exploratory functional efficacy
variables measured at baseline, Week 13, and Week 25
were summarized using summary statistics. Non-parametric
methods were used as part of a sensitivity analysis. We
found the results robust, but choose to provide the parametric
method as it better models the data. 
3. Results 
3.1. Study sites 
The study was carried out at 17 centers (seven in the
United States, three in France, three in Germany, and at
one center each in Belgium, Denmark, Netherlands, and the
United Kingdom). Study sites and NEO1 investigators are
listed in Supplementary Table S2. 
3.2. Patient disposition 
The first patient was enrolled into the study on August
19, 2013 and the last completed the study on February 25,
2015. In total, 24 patients were enrolled and treated ( Fig.
3 ); 10 patients in the Naïve Group (5 mg/kg, n = 4; 10 mg/kg, = 3; 20 mg/kg, n = 3) and 14 patients in the Switch Group
5 mg/kg, n = 4; 10 mg/kg, n = 4; 20 mg/kg, n = 6). In the Naïve
roup, 1 patient in the 5 mg/kg group discontinued treatment
ue to serious AEs (SAEs) of respiratory distress and chest
iscomfort; these occurred during the ninth avalglucosidase
lfa infusion and were considered IARs. In the Switch
roup, 2 patients discontinued treatment for non-AE-related
easons (1 patient in the 5 mg/kg group following the last
valglucosidase alfa infusion and 1 patient in the 20 mg/kg
roup following their eighth avalglucosidase alfa infusion). 
.3. Demographics and Pompe disease history 
Patient demographics and Pompe disease history for the
verall Naïve and Switch Groups are presented in Table 1
nd by treatment groups in Supplementary Table S3. Overall,
n the Naïve and Switch Groups, 30% (3/10) and 64% (9/14),
espectively, of patients were male, and most were Caucasian
88% [21/24]). A confirmed Pompe disease family history
as recorded in 42% (10/24) of patients and 38% (9/24) had
n affected sibling. 
Mean ±SD age of patients at Pompe disease diagnosis was
3.3 ±23.8 years for the Naïve Group and 36.3 ±16.4 years for
he Switch Group. Median ages of patients at Pompe disease
iagnosis were similar for the two groups (Naïve Group: 36.4
L.D.M. Pena, R.J. Barohn and B.J. Byrne et al. / Neuromuscular Disorders 29 (2019) 167–186 173 
Table 1 
Demographic characteristics and Pompe disease history. 
Parameter Naïve Group (alglucosidase alfa 
treatment-naïve Pompe disease 
patients; n = 10) 
Switch Group (Pompe disease patients 
previously treated with alglucosidase 
alfa for ≥9 months; n = 14) 
Age at study enrollment, years, mean ± SD 44.8 ± 20.26 46.7 ± 14.11 
Sex, female/male, n (%) 7 (70)/3 (30) 5 (36)/9 (64) 
Race, n (%) 
Black or African American 0 (0) 1 (7) 
White 8 (80) 13 (93) 
Multiple 1 (10) 0 (0) 
Other 1 (10) 0 (0) 
Hispanic/non-Hispanic, n (%) 0 (0)/10 (100) 0 (0)/14 (100) 
Height, cm, mean ± SD 170.8 ± 8.20 176.3 ± 10.82 
Weight, kg, mean ± SD 65.0 ± 9.85 76.7 ± 15.84 
Body mass index, kg/m 2 , mean ± SD (median [range]) 22.3 ± 3.14 
(23.2 [17.0 −26.1]) 
24.6 ± 3.69 
(24.1 [17.0 −31.0]) 
Age at Pompe disease diagnosis, years, mean ± SD (median [range]) 43.3 ± 23.79 ∗
(36.4 [15.8, 78.2]) 
36.3 ± 16.39 † 
(34.2 [3.4, 62.9]) 
Pompe disease family history, yes/no, n (%) 4 (40)/6 (60) 6 (43)/8 (57) 
If yes, relationship to patient, siblings/cousins, n (%) 3 (30)/1 (10) 6 (43)/0 (0) 
Assistive walking devices and orthoses, n (%) 
None 8 (80) 11 (79) 
Rolling walker 1 (10) 1 (7) 
Straight cane 0 (0) 2 (14) 
Other: two walking sticks (poles) 1 (10) 0 (0) 
SD, standard deviation. 
∗ n = 8. 
† n = 9. 
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r  range 15.8, 78.2] years; Switch Group: 34.2 [range 3.4, 62.9]
ears). Patients entered the current study at various times
fter initial diagnosis (mean age at study enrollment was
4.8 ±20.3 years for the Naïve Group and 46.7 ±14.1 years for
he Switch Group). In the Switch Group, 9 patients had full
ata for pre-study alglucosidase alfa treatment duration, which
anged from 0.9 to 7.9 years. Overall, 21% (5/24) of patients
sed a walking device at baseline (Naïve Group: 20%; Switch
roup: 21%). 
During the study, 7 patient samples were genotyped
or pathogenic GAA variants and the remaining genotypes
ere retrieved from historic patient data. All genotypes
ere consistent with an LOPD diagnosis. Eighteen patients
ad the common c.-32-13T > G splice variant in compound
eterozygosity with another GAA pathogenic variant. Six
atients had two pathogenic GAA variants not including c.-
2-13T > G. 
.4. Safety 
.4.1. Adverse events 
In both groups, avalglucosidase alfa was generally well-
olerated at all doses; no deaths or life-threatening SAEs
ere reported. Most treatment-emergent AEs (TEAEs) were
on-serious, with mild-to-moderate intensity (95% [169/176]). 
egardless of relationship to treatment, overall, 80% (8/10)
f Naïve Group patients and 86% (12/14) of Switch Group
atients experienced ≥1 TEAE, with respective group totals
f 83 and 93 TEAEs. TEAEs considered related to the study
rug ( Table 2 ); occurred in 60% (6/10) of Naïve Groupatients (16 events), and in 50% (7/14) of Switch Group
atients (26 events). The number of patients experiencing ≥1
EAE and the number of events during the study were similar
cross all doses and for each group. 
In the Naïve Group, across all doses, common TEAEs
egardless of their relationship to study drug included
eadache (8 events in 4 patients), rash (8 events in 3 patients),
izziness (7 events in 3 patients), nausea (4 events in 3
atients), oral herpes (4 events in 1 patient), dysmenorrhea
4 events in 2 patients), and diarrhea (3 events in 3
atients). In the Switch Group, across all doses, common
EAEs regardless of their relationship to study drug included
eadache (10 events in 3 patients), myalgia (6 events in 1
atient), musculoskeletal pain (4 events in 3 patients), falls
4 events in 2 patients), and nasopharyngitis (3 events in 3
atients). 
In the Naïve Group, there were two study drug-related
AEs (respiratory distress and chest discomfort) reported by
 patient in the 5 mg/kg group at the ninth infusion (Week
7); both were study drug-related IARs and led to treatment
iscontinuation and study withdrawal. The TEAE of chest
iscomfort was considered to be severe and began 3 min
nto infusion along with a cough (moderate). Three minutes
ater the TEAE of respiratory distress began and flushing
 min later; both were considered moderate in intensity.
ll TEAEs resolved, with the flushing and chest discomfort
esolving approximately 7–9h after onset, the TEAE of
ough resolving approximately 1.5 days later, and respiratory
istress resolving 3 days later. In addition, the patient
eported dizziness and nausea, which occurred following
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Table 2 
Number (%) of patients with study drug-related treatment-emergent adverse events by Medical Dictionary for Regulatory Activities (MedDRA) preferred 
term. 
MedDRA: Preferred term Naïve Group (alglucosidase alfa 
treatment-naïve Pompe disease 
patients; n = 10) 
Switch Group (Pompe disease patients 
previously treated with alglucosidase 
alfa for ≥9 months; n = 14) 
Patients, n (%) Patients, n (%) 
Any events 6 (60) 7 (50) 
Fatigue 2 (20) 1 (7) 
Nausea 2 (20) 0 (0) 
Abdominal pain 0 (0) 1 (7) 
Asthenia 0 (0) 1 (7) 
Balanoposthitis 0 (0) 1 (7) 
Chest discomfort 1 (10) 0 (0) 
Cough 1 (10) 0 (0) 
Diarrhea 0 (0) 1 (7) 
Dizziness 1 (10) 1 (7) 
Dyspnea 1 (10) 1 (7) 
Erythema 1 (10) 0 (0) 
Facial pain 0 (0) 1 (7) 
Flushing 1 (10) 0 (0) 
Gastroesophageal reflux disease 1 (10) 0 (0) 
Headache 1 (10) 1 (7) 
Hypersensitivity 0 (0) 1 (7) 
Hypotension 0 (0) 1 (7) 
Infusion site reaction 0 (0) 1 (7) 
Muscle spasms 0 (0) 1 (7) 
Myalgia 1 (10) 1 (7) 
Pruritus 0 (0) 1 (7) 
Pulmonary function test decreased 0 (0) 1 (7) 
Rash 1 (10) 1 (7) 
Respiratory distress 1 (10) 0 (0) 
Somnolence 0 (0) 1 (7) 
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t  treatment with 50 mg IV diphenhydramine hydrochloride.
The patient received epinephrine during the IAR and had
not received pre-infusion antipyretics, antihistamines, or
steroids. 
In the Switch Group, 1 patient in the 5 mg/kg group
experienced one treatment-emergent SAE (gastrointestinal
hemorrhage), which did not lead to treatment discontinuation
or study withdrawal, and was not considered study drug-
related. 
For both groups, the majority of TEAEs were mild across
all dose levels. Fifteen of the 24 enrolled patients reported
having used concomitant medications during the study for
TEAEs. 
3.4.2. Infusion-associated reactions 
Overall, 25 IARs were reported/identified in 8 patients
across both groups. 
In the Naïve Group, 40% (4/10) of patients reported a total
of 11 IARs; the most commonly reported (2/11 IARs) was
flushing; all other IARs occurred once. All IARs were non-
serious except for the two IARs in the patient at 5 mg/kg that
led to study withdrawal as described in Section 3.4.1 . This
patient experienced six IARs (chest discomfort [SAE], cough,
respiratory distress [SAE], flushing, dizziness, and nausea) at
the ninth avalglucosidase alfa infusion (Week 17). The patient
had also experienced IARs of rash following the second
infusion and flushing following the eighth infusion; at theime both were considered possibly study drug-related. This
atient was negative for anti-avalglucosidase alfa antibodies
t screening and seroconverted at Week 13 with a titer of
600; immediately before the ninth infusion the titer was
200. Further samples collected following the ninth infusion
ere negative for anti-avalglucosidase alfa IgE antibodies,
ositive for complement activation, and tryptase (3.6 μg/L)
as within the normal range (i.e., ≤12.5 μg/L). None of the
nti-avalglucosidase alfa antibodies inhibited enzyme uptake
r enzymatic activity. 
One Naïve Group patient at 20 mg/kg experienced an IAR
f erythema following the fourth infusion. The patient was
egative for anti-avalglucosidase alfa antibodies at screening
nd seroconverted at Week 9, with sustained antibody titers
anging from 400 to 800 until study end. Samples collected
ollowing this event were negative for anti-avalglucosidase
lfa IgE antibodies and complement activation, and tryptase
2.4 μg/L) was within the normal range. None of the anti-
valglucosidase alfa antibodies inhibited enzyme uptake or
nzymatic activity. 
In the Switch Group, 29% (4/14) of patients reported 14
ARs; all were non-serious. The most common IARs were
yalgia (6 events in 1 patient) and headache (2 events in
 patient), with all other IARs occurring only once. Three
ARs (hypersensitivity, pruritus, and generalized rash) were
eported by 1 Switch Group patient at 20 mg/kg during the
hirteenth avalglucosidase alfa infusion. Samples collected
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t  n association with these IARs were negative for anti-
valglucosidase alfa IgE antibodies, positive for complement
ctivation, and tryptase (4.7 μg/L) was within the normal
ange. 
.4.3. ECG assessments and clinically relevant laboratory 
bnormalities 
There were no individual clinically relevant abnormalities
n ECG data for any patients. In the Switch Group, 2
atients had clinically relevant laboratory abnormalities. One
atient (10 mg/kg group) had hypokalemia in Week 15,
hich was considered a mild TEAE, unlikely related to
valglucosidase alfa, and was resolved by Week 17, with no
equirement for concomitant medication. The other patient
5 mg/kg group) had severe TEAEs of hypovolemia and
nemia, which began on Day 48, 3 days following the fourth
nfusion; this is the same patient who experienced a SAE of
 gastrointestinal bleed on Day 48 (as mentioned in Section
.4.1 .) Neither the gastrointestinal bleed nor the associated
EAEs were considered related to avalglucosidase alfa. The
ypovolemia and anemia resolved after approximately 3 and
 months, respectively; both were treated with concomitant
edications. 
.4.4. Immunogenicity 
In the Naïve Group, 90% (9/10) of patients developed
ntibodies to avalglucosidase alfa during treatment, with a
edian peak titer of 1600 (range 200–25,600) observed across
ll treatments. Mean time to seroconversion from first infusion
as 56.9 ±14.9 (median 56 [range 28–87]) days, with the
eak titer occurring on average 108.4 ±37.7 (median 89 [range
7–175]) days from first infusion. After seroconversion, 1
atient had sustained and elevated titers (defined by protocol
s a peak titer ≥25,600, and a last titer that was equal to,
igher than, or one 2-fold dilution level lower than the peak
iter); this patient’s peak titer was 25,600. This patient showed
mprovement on pulmonary and motor function testing. Two
atients who had seroconverted had decreased titers later (i.e.,
t least 4-fold lower than the peak titer); 1 of these patients
ecreased by 8-fold (three dilution levels), and the other
atient was negative for antibodies at the final time point after
 peak titer of 1600, suggesting that this patient may have
olerized. One patient (5 mg/kg) tested positive for uptake-
nhibitory antibodies at Week 27; no anti-avalglucosidase
lfa antibodies inhibited enzymatic activity. As noted in
ection 3.4.2 ., 2 Naïve Group patients tested negative for anti-
valglucosidase alfa IgE. 
In the Switch Group, 36% (5/14) of patients tested
ositive for antibodies to avalglucosidase alfa at screening,
ith a maximum titer of 1600 observed at Week 1. Titers
n 2 of the 5 patients demonstrated a treatment-boosted
esponse with 4- and 8-fold increased titers from the
aseline levels, with a maximum titer of 12,800. Of the
 patients who tested negative at screening and Week 1
or anti-avalglucosidase alfa antibodies, 2 (22%) patients
eroconverted after Week 1, with a maximum titer of 1600.verall mean time to avalglucosidase alfa seroconversion was
.7 ±46.6 (median –12.0 [range –44.0 to 84.0]) days from
rst on-study infusion (Week 1). Peak titers for patients
ho seroconverted or exhibited a boosted response ( n = 4)
ccurred on average 143 ±27.0 (median 142 [range 111–175])
ays after first infusion. For the 5 patients with pre-study
ositive antibodies and 2 patients who seroconverted during
he study, the median peak titer was 400 (range 200–12,800).
o patient had sustained and elevated titers, and 2 patients
14.3%) had decreased titers (which may be within-assay
ariability, as none decreased > 2-fold). None of the anti-
valglucosidase alfa antibodies inhibited enzyme uptake or
nzymatic activity. At Week 1, 50% (7/14) of Switch Group
atients tested positive for IgG antibodies to alglucosidase
lfa, with a maximum titer of 6400. Of the 7 Switch Group
atients who tested negative at Week 1 for anti-alglucosidase
lfa antibodies, 3 patients seroconverted with antibodies to
lglucosidase alfa during avalglucosidase alfa treatment, with
 maximum observed titer of 3200 (range 1600–3200). As
oted in Section 3.4.2 ., 1 patient in the Switch Group tested
egative for anti-avalglucosidase alfa IgE. 
.5. Pharmacokinetics 
Pharmacokinetics for the Naïve and Switch Groups are
resented in Tables 3 and 4 , respectively. In both the
aïve and Switch Groups, avalglucosidase alfa exposure
ncreased with dose (in the 20 mg/kg group the AUC was
pproximately 5–6 ×greater than in the 5 mg/kg); mean
ystemic CL ranged from 0.92 to 1.28 L/h and 1.0 to 1.57 L/h,
espectively, and mean V ss ranged from 2.40 to 3.02 L and
.83 to 3.71 L, respectively. Within each treatment group,
he pharmacokinetic parameters appeared similar at Weeks
, 13, and 25, indicating no apparent effect of every-other-
eek dosing on avalglucosidase alfa pharmacokinetics. The
harmacokinetic parameters also appeared generally similar
etween the Naïve and Switch groups. 
The mean avalglucosidase alfa plasma concentration–
ime profiles are presented in Fig. 4 A–C. In both groups,
valglucosidase alfa plasma concentrations appeared to 
ecline monoexponentially from 8 to 12 h after the end
f the infusion; mean t ½z ∼1.0 h for each group (range
.66–1.53 h). However, consistent avalglucosidase alfa plasma
oncentrations of approximately 20 ng/mL were observed
rom approximately 12 h post infusion to the last sample
aken, likely representing the endogenous enzyme levels. For
oth groups, the accumulation ratios at Weeks 13 and 25,
ased on AUC values, were generally close to 1.0, which
as consistent with the short t ½z and every-other-week dosing
egimen. 
.6. Pharmacodynamics 
Quadriceps biopsies were available at baseline and Week
7 for 9 patients who completed the study in each of
he Naïve and Switch groups. Mean ±SD quadriceps muscle
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Table 3 
Avalglucosidase alfa pharmacokinetic parameters for alglucosidase alfa treatment-naïve Pompe disease patients (Naïve Group). 
Parameter Week ∗ Avalglucosidase alfa 
5 mg/kg ( n = 4, Week 1; 
n = 3 Weeks 13 and 25) 
10 mg/kg ( n = 3) 20 mg/kg ( n = 3) 
C max , ng/mL, mean ± SD 
(geometric mean) [CV%] 
1 82,300 ± 6690 
(82,100) [8.1] 
190,000 ± 40,100 
(187,000) [21.1] 
302,000 ± 107,000 
(291,000) [35.6] 
13 98,700 ± 38,900 
(93,700) [39.4] 
151,000 ± 29,700 
(149,000) [19.7] 
357,000 ± 185,000 
(329,000) [51.7] 
25 89,100 ± 11,000 
(88,600) [12.3] 
162,000 ± 26,500 
(161,000) [16.4] 
350,000 ± 105,000 
(341,000) [29.9] 
t max , h, median (min −max) 1 1.71 (1.47 −2.58) 2.30 (2.23 −2.30) 3.83 (3.75 −4.00) 
13 1.60 (1.50 −1.80) 2.33 (1.48 −2.35) 3.92 (3.75 −4.00) 
25 1.43 (1.43 −1.62) 2.35 (2.35 −2.45) 3.92 (3.75 −4.50) 
AUC last , ng ·h/mL, mean ± SD 
(geometric mean) [CV%] 
1 259,000 ± 37,600 
(259,000) [14.5] 
529,000 ± 79,600 
(525,000) [15.0] 
1,520,000 ± 806,000 
(1,400,000) [53.0] 
13 285,000 ± 82,900 
(276,000) [29.1] 
529,000 ± 41,800 
(528,000) [7.9] 
1,660,000 ± 1,030,000 
(1,470,000) [62.2] 
25 264,000 ± 50,200 
(261,000) [19.0] 
565,000 ± 89,800 
(560,000) [15.9] 
1,560,000 ± 637,000 
(1,490,000) [40.7] 
AUC, ng ·h/mL, mean ± SD 
(geometric mean) [CV%] 
1 259,000 ± 37,600 
(257,000) [14.5] 
529,000 ± 79,600 
(525,000) [15.0] 
1,520,000 ± 806,000 
(1,400,000) [53.0] 
13 285,000 ± 82,900 
(276,000) [29.1] 
529,000 ± 41,900 
(528,000) [7.9] 
1,660,000 ± 1,030,000 
(1,470,000) [62.2] 
25 264,000 ± 50,200 
(261,000) [19.0] 
565,000 ± 89,800 
(560,000) [15.9] 
1,560,000 ± 637,000 
(1,490,000) [40.7] 
t ½z , h, mean ± SD 
(geometric mean) [CV%] 
1 0.784 ± 0.369 
(0.727) [47.1] 
0.833 ± 0.493 
(0.750) [59.2] 
0.778 ± 0.217 
(0.757) [27.9] 
13 1.34 ± 1.05 
(1.10) [78.2] 
0.738 ± 0.133 
(0.730) [18.1] 
1.34 ± 0.753 
(1.20) [56.0] 
25 0.777 ± 0.0455 
(0.776) [5.9] 
0.856 ± 0.235 
(0.835) [27.5] 
1.03 ± 0.242 
(1.01) [23.5] 
CL, mL/h, mean ± SD 
(geometric mean) [CV%] 
1 1260 ± 203 
(1240) [16.2] 
1240 ± 386 
(1190) [31.3] 
989 ± 278 
(959) [28.1] 
13 1220 ± 307 
(1190) [25.2] 
1280 ± 261 
(1270) [20.3] 
954 ± 335 
(909) [35.1] 
25 1230 ± 229 
(1220) [18.5] 
1180 ± 176 
(1170) [14.9] 
917 ± 214 
(901) [23.4] 
V ss , mL, mean ± SD 
(geometric mean) [CV%] 
1 2620 ± 396 
(2600) [15.1] 
2480 ± 626 
(2420) [25.3] 
2900 ± 439 
(2870) [15.2] 
13 2650 ± 803 
(2540) [30.3] 
3020 ± 766 
(2960) [25.4] 
2910 ± 661 
(2860) [22.7] 
25 2400 ± 316 
(2390) [13.1] 
2670 ± 109 
(2670) [4.1] 
2930 ± 233 
(2930) [7.9] 
t last , h, median (min −max) 1 9.63 (9.57 −17.77) 12.47 (12.43 −12.47) 19.75 (13.92 −20.00) 
13 14.69 (9.83 −33.50) 14.33 (12.67 −15.28) 19.75 (15.25 −23.92) 
25 12.53 (9.62 −13.82) 14.10 (12.60 −18.47) 20.50 (15.92 −23.75) 
C last , ng/mL, mean ± SD 
(geometric mean) [CV%] 
1 65.8 ± 102 
(29.2) [154.4] 
13.0 ± 0.00 
(13.0) [0.0] 
23.7 ± 8.08 
(22.8) [34.2] 
13 18.5 ± 7.14 
(17.6) [38.6] 
19.3 ± 3.21 
(19.2) [16.6] 
36.0 ± 4.58 
(35.8) [12.7] 
25 64.3 ± 72.5 
(42.1) [112.7] 
24.3 ± 7.77 
(23.6) [31.9] 
45.3 ± 15.0 
(43.4) [33.1] 
Accumulation ratio (AUC) 13 1.10 1.00 1.09 
25 1.02 1.07 1.03 
AUC, area under the plasma concentration–time curve extrapolated to infinity; AUC last , area under the plasma concentration–time curve calculated using the 
trapezoidal method from last time point attributable to the administered drug; CL, apparent total body clearance from the plasma; C last , last concentration 
above the limit of quantitation considered to be due to administered drug effect; C max , maximum plasma concentration observed; CV, coefficient of variation; 
SD, standard deviation; t ½z , terminal half-life; t last , time corresponding to the last time point attributable to the administered drug and above the limit of 
quantitation, C last ; t max , time to reach C max ; V ss , mean steady-state volume of distribution. 
∗ Week 1, 1st infusion; Week 13, 7th infusion; Week 25, 13th infusion. 
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Table 4 
Avalglucosidase alfa pharmacokinetic parameters for Pompe disease patients previously treated with alglucosidase alfa for ≥9 months (Switch Group). 
Parameter Week ∗ Avalglucosidase alfa 
5 mg/kg ( n = 4) 10 mg/kg ( n = 4) 20 mg/kg ( n = 6, Week 1 
and 13; n = 5, Week 25) 
C max , ng/mL, mean ± SD 
(geometric mean) [CV%] 
1 77,400 ± 22,400 
(74,800) [29.0] 
168,000 ± 36,800 
(165,000) [21.9] 
321,000 ± 125,000 
(303,000) [38.9] 
13 103,000 ± 42,800 
(96,300) [41.4] 
171,000 ± 45,100 
(166,000) [26.4] 
327,000 ± 90,200 
(317,000) [27.6] 
25 97,100 ± 36,400 
(90,900) [37.6] 
164,000 ± 19,100 
(163,000) [11.6] 
299,000 ± 47,500 
(296,000) [15.9] 
t max , h, median (min −max) 1 1.84 (1.38 −2.60) 2.27 (1.75 −2.43) 3.83 (3.68 −4.73) 
13 1.64 (1.52 −2.58) 2.44 (2.28 −2.72) 3.86 (3.58 −4.23) 
25 1.97 (1.50 −2.62) 2.51 (2.25 −3.35) 3.83 (3.68 −5.58) 
AUC last , ng ·h/mL, mean ± SD 
(geometric mean) [CV%] 
1 246,000 ± 81,500 
(236,000) [33.1] 
631,000 ± 118,000 
(622,000) [18.7] 
1,500,000 ± 502,000 
(1,430,000) [33.4] 
13 296,000 ± 84,200 
(288,000) [28.4] 
668,000 ± 186,000 
(646,000) [27.9] 
143,0000 ± 529,000 
(1,350,000) [37.0] 
25 306,000 ± 79,900 
(298,000) [26.1] 
642,000 ± 46,900 
(641,000) [7.3] 
1,530,000 ± 434,000 
(1,480,000) [28.5] 
AUC, ng ·h/mL, mean ± SD 
(geometric mean) [CV%] 
1 246,000 ± 81,500 
(236,000) [33.1] 
631,000 ± 118,000 
(622,000) [18.7] 
1,500,000 ± 502,000 
(1,430,000) [33.4] 
13 296,000 ± 84,200 
(288,000) [28.4] 
668,000 ± 186,000 
(646,000) [27.9] 
1,430,000 ± 529,000 
(1,350,000) [37.0] 
25 306,000 ± 79,900 
(298,000) [26.1] 
642,000 ± 46,900 
(641,000) [7.3] 
1,530,000 ± 434,000 
(1,480,000) [28.5] 
t ½z , h, mean ± SD 
(geometric mean) [CV%] 
1 0.668 ± 0.299 
(0.628) [44.8] 
1.03 ± 0.628 
(0.920) [61.1] 
0.876 ± 0.232 
(0.852) [26.5] 
13 0.656 ± 0.253 
(0.626) [38.5] 
0.838 ± 0.214 
(0.821) [25.5] 
0.849 ± 0.254 
(0.816) [29.9] 
25 1.53 ± 0.520 
(1.47) [33.8] 
0.712 ± 0.103 
(0.706) [14.5] 
1.06 ± 0.435 
(1.00) [40.9] 
CL, mL/h, mean ± SD 
(geometric mean) [CV%] 
1 1570 ± 362 
(1530) [23.1] 
1280 ± 246 
(1270) [19.2] 
1060 ± 198 
(1050) [18.6] 
13 1290 ± 319 
(1260) [24.7] 
1280 ± 448 
(1230) [35.1] 
1160 ± 321 
(1120) [27.6] 
25 1240 ± 342 
(1210) [27.7] 
1230 ± 56.3 
(1230) [4.6] 
998 ± 204 
(982) [20.5] 
V ss , mL, mean ± SD 
(geometric mean) [CV%] 
1 3710 ± 1520 
(3490) [40.9] 
3210 ± 839 
(3140) [26.1] 
3310 ± 731 
(3250) [22.1] 
2830 ± 762 
(2750) [26.9] 
3280 ± 1080 
(3170) [32.9] 
3510 ± 952 
(3390) [27.2] 
25 2880 ± 704 
(2820) [24.4] 
3060 ± 114 
(3060) [3.7] 
3290 ± 755 
(3210) [23.0] 
t last , h, median (min −max) 1 9.68 (9.60 −17.67) 14.47 (14.33 −26.50) 17.87 (15.75 −21.03) 
13 9.62 (9.60 −18.67) 14.48 (14.28 −18.67) 17.95 (11.75 −21.83) 
25 20.04 (13.58 −25.75) 14.34 (12.70 −14.35) 16.77 (15.67 −21.58) 
C last , ng/mL, mean ± SD 
(geometric mean) [CV%] 
1 19.0 ± 5.48 
(18.5) [28.8] 
15.8 ± 1.71 
(15.7) [10.8] 
29.7 ± 19.5 
(25.4) [65.7] 
13 19.0 ± 4.08 
(18.7) [21.5] 
19.3 ± 4.57 
(18.8) [23.8] 
34.8 ± 16.8 
(32.0) [48.2] 
25 23.8 ± 12.7 
(21.1) [53.6] 
22.5 ± 10.5 
(21.0) [46.5] 
47.8 ± 33.7 
(40.3) [70.4] 
Accumulation ratio (AUC) 13 1.20 1.06 0.95 
25 1.24 1.02 1.02 
AUC, area under the plasma concentration–time curve extrapolated to infinity, AUC last , area under the plasma concentration–time curve calculated using the 
trapezoidal method from last time point attributable to the administered drug; CL, apparent total body clearance from the plasma; C last , last concentration 
above the limit of quantitation considered to be due to administered drug effect; C max , maximum plasma concentration observed; CV, coefficient of variation; 
SD, standard deviation; t ½z , terminal half-life; t last , time corresponding to the last time point attributable to the administered drug and above the limit of 
quantitation, C last ; t max , time to reach C max ; V ss , mean steady-state volume of distribution. 
∗ Week 1, 1st infusion; Week 13, 7th infusion; Week 25, 13th infusion. 
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Fig. 4. Mean avalglucosidase alfa plasma concentrations following every-other-week infusions of avalglucosidase alfa ( n = 3 to 6 per dose level). (a) Week 1, 
(b) Week 13, and (c) Week 25. Limit of quantitation (LoQ) = 13 ng/mL. 
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Fig. 5. Evaluation of intact muscle and fatty replacement by MRI (a) Mercuri score, (b) 3-point Dixon, (c) T 2 with B 1 , and (d) T 2 without B 1 . 
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nlycogen content at baseline was 6.0 ±7.3% in the Naïve
roup and 6.5 ±7.9% in the Switch Group. For most patients,
uadriceps muscle glycogen levels remained unchanged from
aseline to Week 27 (see Supplementary Fig. S1A and B). 
Urinary Hex 4 concentrations over time for individual
atients in the Naïve and Switch groups are shown in
upplementary Fig. S2A and B, respectively. At Week 13,
cross both groups, mean ±SD % changes from baseline in
rinary Hex 4 concentrations decreased at all avalglucosidase
lfa dose levels, except in the 5 mg/kg Switch Group
4.3 ±8.8%). At Week 25, the % changes from baseline were:
aïve Group: –30.3 ±18.6%, –36.0 ±6.9%, and –13.2 ±40.6%
or the 5, 10, and 20 mg/kg avalglucosidase alfa groups,
espectively, and Switch Group: –7.5 ±38.8%, –12.0 ±29.7%,
nd –20.5 ±27.8% for the 5, 10, and 20 mg/kg avalglucosidase
lfa groups, respectively. 
Evaluation of intact muscle and fatty replacement in the
pper leg (thigh) and lower leg with Mercuri scores, 3-
oint Dixon, and T 2 MRI with and without B 1 mapping,emonstrated minimal changes throughout the study for
oth Naïve and Switch Group patients ( Fig. 5 A–D). Similar
ndings were observed across both groups. In the Naïve
roup, some changes from baseline in the upper leg 3-point
ixon parameter at Week 27 corresponded to nominal p -
alues of < 0.05 for the 5 and 10 mg/kg, and overall groups
19.4% change [95% CI: 1.0, 37.9], p = 0.0438; 20.6% change
95% CI: 14.4, 26.9], p = 0.0153; and 15.9% change [95%
I: 6.6, 25.2], p = 0.0050, respectively). In the Switch Group
t Week 27, some changes from baseline corresponded to
ominal p-values of < 0.05; these were the for the upper
nd lower legs T 2 without B 1 for the 5 mg/kg group (12.3%
95% CI: 5.0, 19.6], p = 0.0185 and 5.0% [95% CI: 0.5, 9.5],
 = 0.0413, respectively) and for the lower leg T 2 with B 1 for
he overall group (2.5% [95% CI 0.1, 4.8], p = 0.0451). For
oth the Naïve and Switch Groups, all other % changes from
aseline at Week 27 for the four pharmacodynamics response
arameters in any treatment group or overall did not reach
ominal significance. 
180 L.D.M. Pena, R.J. Barohn and B.J. Byrne et al. / Neuromuscular Disorders 29 (2019) 167–186 
Fig. 6. Upright % predicted forced vital capacity (FVC), maximal expiratory pressure (MEP), and minimal inspiratory pressure (MIP) for individual patients 
and treatment means. 
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a  3.7. Exploratory efficacy 
3.7.1. Pulmonary function 
Upright % predicted FVC, MEP, and MIP for individual
patients along with treatment means at baseline, and Weeks 13
and 25 for the Naïve and Switch Groups are shown in Fig.
6 (see Supplementary Table S4 for the mean ±SD, median,
minimum, and maximum FVC, MEP, and MIP values atach time point, along with mean % change from baseline
t Week 25 for each treatment). In both groups, pulmonary
unction generally improved or was stable at Week 25 relative
o baseline. 
.7.2. 6MWT 
The % predicted 6MWT distances for individual patients
nd treatment means are shown in Fig. 7 (Supplementary
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Fig. 7. 6-min walk test (6MWT) % predicted, (a) Naïve Group and (b) Switch Group. 
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f  able S5 shows a summary of mean ±SD, median, minimum,
nd maximum % predicted 6MWT distances at baseline and
eek 25, along with changes from baseline at Week 25 for
oth groups by dose level). At baseline, during the 6MWT
atients in the Naïve Group walked a mean ±SD total distance
f 449 ±118 (range 208–593) m and those in the Switch
roup walked total distance of 440 ±141 (range 201–657)
. In the Naïve Group, mean ±SD changes from baseline
n 6MWT distances were 12.0 ±21.0 m, –15.3 ±15.5 m, and
4.3 ±23.0 m for the 5, 10, and 20 mg/kg groups, respectively,
nd for the Switch Group they were –4.0 ±30.5 m, 4.3 ±8.1 m,
nd –6.2 ±64.3 m, respectively. 
.7.3. GSGC test 
For the Naïve and Switch Groups, mean changes from
aseline at Week 25 for functional ability GSGC score
emained unchanged relative to baseline at all doses, with
verall means of –0.8 for the Naïve Group and 0.2 for the
witch Group. 
The GSGC combines timed tests for walking 10 m,
limbing four stairs, standing from sitting on the floor and
tanding from sitting on a chair. Although, the total score
or these four tests did not change over the course of
he study, test results for selected subtests showed mean
ecreases in both Naïve and Switch Group patients. The
ean ±SD changes from baseline for times to walk 10 m,
limb four stairs, stand from sitting on the floor, and stand
rom sitting on a chair at Week 25 for the overall Naïve
roup were –0.6 ±1.01 s, –1.1 ±2.21 s, –3.0 ±6.72 s, and –
.2 ±0.86 s, respectively, and for the overall Switch Group
ere –0.4 ±2.73 s, –0.5 ±2.83 s, 1.7 ±3.12 s, and –0.1 ±0.72 s,
espectively. 
.7.3. GMFM-88 test 
GMFM-88-DE scores for individual patients and treatment
eans are shown in Fig. 8 A and B, for the Naïve andwitch Groups, respectively. For both groups, mean scores
or Dimensions D (standing) and E (walking, running,
nd jumping), and the combined GMFM-88-DE functional
trength total assessments remained unchanged relative to
aseline in all treatment groups. The % mean ±SD change
rom baseline for GMFM-88-DE score at Week 25 for the
verall Naïve Group was 3.0 ±5.9% and for the overall Switch
roup was 2.2 ±9.0%. 
.7.4. QMFT 
QMFT scores for individual patients and treatment means
re shown in Fig. 8 C and D, for the Naïve and Switch Groups,
espectively. In the Naïve Group, the mean ±SD QMFT scores
hanged relative to baseline at Week 25 in the 5, 10, and
0 mg/kg groups by 0.7 ±4.9, 1.7 ±2.3, and 3.0 ±2.7 points,
espectively, whilst in the Switch Group they changed by
1.5 ±2.7, 3.0 ±1.6, and 1.2 ±1.9 points, respectively. 
.7.5. HHD test 
Lower body HHD scores for individual patients and
reatment means are shown in Fig. 8 E and F, for the Naïve and
witch Groups, respectively. In the Naïve Group, lower body
HD assessments changed at Week 25 relative to baseline by
 mean ±SD of 11.6 ±4.7%, 21.4 ±10.3%, and 14.2 ±15.9%
n the 5, 10, and 20 mg/kg groups, respectively, whilst for
he upper body assessments they changed by 8.2 ±25.9%,
9.0 ±7.5%, and –9.9 ±16.9%, respectively. In the Switch
roup, lower body HHD assessments changed at Week 25
elative to baseline by –0.5 ±13.1%, 14.3 ±27.3%, and –
4.5 ±42.2% in the 5, 10, and 20 mg/kg groups, respectively,
hilst for the upper body assessments they changed by
8.1 ±24.5%, 10.8 ±17.8%, and –15.3 ±27.7%, respectively. 
.7.6. PedsQL 
For both groups, mean scores for cognitive fatigue, general
atigue, and sleep/rest fatigue were mostly unchanged relative
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Fig. 8. Gross Motor Function Measure-88 for Dimensions D and E (GMFM-88-DE), Quick Motor Function Test (QMFT), and Hand-Held Dynamometry 
(HHD) sum of lower body for the Naïve Group (a, c, and e, respectively) and the Switch Group (b, d, and f, respectively). 
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e  to baseline. However, in the Naïve Group, there was a
mean ±SD increase in cognitive fatigue from baseline at
Week 25 in the 5 mg/kg group (–13.9 ±6.4) and a decrease
in cognitive fatigue and general fatigue (11.1 ±9.6 and
8.3 ±7.2, respectively) in the 20 mg/kg group. For the Switch
Group, the two greatest increases in fatigue from baseline
at Week 25 were for general fatigue in the 5 mg/kg group (–
12.5 ±4.8) and for sleep/rest fatigue, also in the 5 mg/kg group
(–6.2 ±4.2). . Discussion 
In this open-label, ascending-dose study, avalglucosidase
lfa was generally safe and well-tolerated at doses of 5,
0, and 20 mg/kg in adult patients with Pompe disease
ho were either treatment-naïve or had previously been
reated with alglucosidase alfa for ≥9 months. No deaths
r life-threatening SAEs were reported. Three treatment-
mergent SAEs were reported by 2 patients. One Naïve Group
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a  5 mg/kg) patient reported two SAEs of respiratory distress
nd chest discomfort, both were considered study-drug related
nd led to study withdrawal. The other patient who reported
 SAE was in the Switch Group (5 mg/kg) and experienced
astrointestinal hemorrhage, which was not considered study
rug-related and did not lead to treatment discontinuation or
tudy withdrawal. For both groups, the majority of TEAEs
ere mild across all dose levels. Across both groups, 25 IARs
ere reported in 8 (33%) patients. 
Anti-avalglucosidase alfa antibodies were characterized 
ecause rhGAA studies suggest that antibodies to exogenous
AA may affect IARs [48] and/or efficacy in some LOPD
atients [49] . Seroconversion for anti-avalglucosidase alfa
ntibodies was detected in the majority (90%) of Naïve
roup patients and in 2 of 9 (22%) Switch Group
atients, who had no anti-avalglucosidase alfa antibodies
t baseline. Highest peak titers were 25,600 (1 Naïve
roup patient) and 12,800 (1 Switch Group patient); the
atient in the Naïve group improved on pulmonary and
otor function testing and the patient in the Switch group
mproved on pulmonary function testing and declined on
otor function testing. Titers for the remaining Naïve
roup seroconverters remained ≤3200 and for the remaining
witch Group seroconverters remained ≤1600. No patients
ested positive for enzyme activity inhibition, and only
 patient, who was in the Naïve Group, tested positive
or enzyme uptake inhibition. We note the presence
f antibodies to avalglucosidase alfa at baseline in the Switch
roup, which may represent cross-reactivity with common
pitopes from recombinant human GAA. Complement 
ppeared to mediate IARs in 1 patient per group, although
nly 2 Naïve Group and 1 Switch Group patients were tested.
Avalglucosidase alfa plasma concentrations appeared to
ecline monoexponentially following the end of the infusion,
ith a mean t ½z of ∼1.0 h for both groups; consistent
ith avalglucosidase alfa non-clinical data, this was relatively
horter than observed for alglucosidase alfa (2.3 h) [25] .
valglucosidase alfa pharmacokinetics appeared generally 
imilar between groups and avalglucosidase alfa exposure
ncreased with dose. The pharmacokinetic parameters 
ppeared similar at Weeks 1, 13, and 25, indicating no
pparent effect of every-other-week dosing on avalglucosidase
lfa pharmacokinetics. 
Baseline quadriceps muscle biopsy glycogen levels were
enerally low ( ∼6% of tissue area) in both groups and
emained mostly unchanged throughout the study. In addition,
lycogen content is generally low in adults with Pompe
isease and there is limited longitudinal information regarding
lycogen clearance from muscle with enzyme replacement
herapy. In the Exploratory Muscle Biopsy Assessment Study
EMBASSY) of alglucosidase alfa in LOPD [21] , quadriceps
iopsy glycogen was found both in lysosomes and cytoplasm
t baseline (mean 5.3%; range 1.0–14.2%); after 24 weeks’
herapy, lysosomal glycogen decreased in 10 patients and
ncreased in 3 patients. Statistically significant changes were
oted in 6 patients (4 had decreased glycogen and 2 increased
lycogen), while cytoplasmic glycogen remained, and theotal area of glycogen showed small reductions from baseline.
imilarly, a study by Ripolone et al. [50] showed quadriceps
iopsy improvements (e.g., fewer small Periodic Acid–
chiff (PAS)-positive glycogen accumulations and reduced 
everity of vacuolation, using different techniques than in
MBASSY or our study) in 15 of 18 LOPD patients after
6 months of alglucosidase alfa. Thus, biopsy results from
ur current avalglucosidase alfa study appear to be similar to
lglucosidase alfa studies in LOPD. 
Across both groups, urinary Hex 4 levels decreased at all
valglucosidase alfa doses (indicating reduction of glycogen 
urden), except for 5 mg/kg at Week 13 for the Switch
roup. The trend for reduction was most pronounced in the
aïve group, similar to trends described in IOPD patients at
nitiation of enzyme replacement therapy [51] . There was no
lear relationship to dose level. Of note, Hex 4 levels in LOPD
rior to therapy are often not as high as those in IOPD [52] ,
o that post-treatment trends may be less clear-cut in LOPD.
Muscle MRI at baseline indicated relatively mildly affected
atients in both groups, which remained largely stable with
ittle change throughout the 24-week treatment period. These
esults were similar to the EMBASSY study of alglucosidase
lfa in LOPD [21] , in which patients began with a mild degree
f involvement and MRI parameters did not change materially
uring 6 months of treatment. 
In both groups, pulmonary function generally improved or
as stable at Week 25 relative to baseline in most patients.
he evaluation of FVC % predicted is widely used as a
ulmonary function endpoint in Pompe disease [53] and other
euromuscular diseases. In chronic respiratory diseases, FVC
hange over time is a valid measurement [54] . Repeated FVC
 predicted measurement in untreated LOPD has revealed
nnual changes of −1.0% to −4.6% upright and 1.3% to
5.5% supine [54] . MIP and MEP have been evaluated in
nly four published papers on Pompe disease [ 55 –58 ]. 
While efficacy assessments were purely exploratory, for
oth groups, patients remained stable or demonstrated
mprovements via several functional assessments. 6MWT 
istances were generally stable or tended to increase with
valglucosidase alfa, without a clear relationship to patient
roup or dose level. For both groups, GSGC and GMFM-88
ssessments showed minimal changes, whereas improvements 
ere observed in the QMFT and HHD evaluations. Decreases
n cognitive and general fatigue were reported at 20 mg/kg
valglucosidase alfa by Naïve Group patients. Fatigue is
alient in patients’ experience of LOPD, with 2 out
f 3 International Pompe Association survey respondents
dentifying it as among the three most disabling symptoms
59] . Decreased fatigue on avalglucosidase alfa therapy in
aïve patients in our study parallels previous experience of
educed fatigue in alglucosidase alfa recipients [59,60] . 
The focus of this phase 1 study was safety,
harmacokinetic, and pharmacodynamic characteristics 
f avalglucosidase alfa in a small cohort of LOPD patients.
xploratory efficacy parameters demonstrated, in general, 
hat pulmonary function remained stable or improved,
s did functional capacity. The LOTS [28,29] , a study
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 of alglucosidase alfa in children and adults with LOPD,
demonstrated improvement in pulmonary function and
distance walked after 78 weeks of therapy. It is therefore
reassuring that functional and respiratory decline was
not observed during this short period of treatment with
avalglucosidase alfa. 
Our study had some limitations. Firstly, a primary efficacy
period of only 24 weeks precluded assessment of long-term
treatment effects. Secondly, since the study cohort was small,
with only 3–6 patients per dose group, it is difficult to draw
firm conclusions from the data regarding efficacy. Finally,
the design of the study does not allow comparison with
previous safety or immunogenicity data from alglucosidase
alfa studies that were placebo-controlled or open-label and not
dose-escalating. The currently recruiting head-to-head study,
COMET (NCT02782741), will directly compare the efficacy
and safety of avalglucosidase alfa with alglucosidase alfa in
LOPD patients not previously treated for Pompe disease with
enzyme replacement therapy. 
5. Conclusions 
Avalglucosidase alfa had a well-tolerated safety profile in
LOPD patients, either naïve to alglucosidase alfa therapy or
who had previously received alglucosidase alfa therapy for
≥9 months. Whilst the efficacy assessments were exploratory,
the results of this study support further development of
avalglucosidase alfa. 
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